Thompson Siegel & Walmsley LLC Acquires 45,271 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Thompson Siegel & Walmsley LLC grew its holdings in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 78.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,267 shares of the company's stock after purchasing an additional 45,271 shares during the period. Thompson Siegel & Walmsley LLC owned approximately 0.07% of MiMedx Group worth $993,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Jane Street Group LLC lifted its holdings in shares of MiMedx Group by 133.6% in the third quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock valued at $1,806,000 after purchasing an additional 174,797 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of MiMedx Group by 265.4% in the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock worth $1,757,000 after acquiring an additional 215,995 shares during the last quarter. Barclays PLC increased its stake in shares of MiMedx Group by 163.9% in the third quarter. Barclays PLC now owns 262,449 shares of the company's stock worth $1,550,000 after acquiring an additional 163,005 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of MiMedx Group by 79.9% in the fourth quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock worth $802,000 after acquiring an additional 37,031 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of MiMedx Group by 6.3% in the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock worth $328,000 after acquiring an additional 3,292 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company's stock.

Remove Ads

MiMedx Group Stock Up 2.1 %

MiMedx Group stock traded up $0.17 during mid-day trading on Wednesday, hitting $8.09. 440,960 shares of the company's stock were exchanged, compared to its average volume of 694,789. The stock has a market cap of $1.19 billion, a P/E ratio of 14.71 and a beta of 1.97. The stock has a 50 day moving average of $8.42 and a two-hundred day moving average of $7.84. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The company had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Insider Activity

In related news, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the sale, the chief accounting officer now owns 440,178 shares in the company, valued at approximately $3,473,004.42. This trade represents a 11.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. The trade was a 1.30 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 142,259 shares of company stock valued at $1,116,170. 1.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.